GlaxoSmithKline unit Stiefel Laboratories is gearing up for a legal fight with the Securities and Exchange Commission, which sued the company for allegedly duping shareholders out of $110 million.
But at least the lawyers at Greenberg Traurig who’ve signed on to represent Stiefel in the case won’t need long to get up to speed: The firm’s been defending Stiefel in related private litigation for more than two years, ever since the Coral Gables-based company’s $2.9 billion acquisition by GSK.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
